![](/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBHQT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e623d2450603cd9d4e6c86eae39da2c5b7f7bdd9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdERG9MY21WemFYcGxTU0lOTXpJd2VERTRNRjRHT2daRlZEb0pZM0p2Y0VraUVETXlNSGd4T0RBck1Dc3dCanNHVkRvTVozSmhkbWwwZVVraUMyTmxiblJsY2dZN0JsUTZESEYxWVd4cGRIbHBWVG9LYzNSeWFYQlVPZzVwYm5SbGNteGhZMlZKSWdsTWFXNWxCanNHVkRvTFpHVm1hVzVsU1NJZWFuQmxaenBtWVc1amVTMTFjSE5oYlhCc2FXNW5QVzltWmdZN0JsUT0iLCJleHAiOm51bGwsInB1ciI6InZhcmlhdGlvbiJ9fQ==--daee5f4cd191d67586af9b48495fbde7d4763d64/lucas-vasques-453684-unsplash.jpg)
Search
Selected Filters
Filter Results
Displaying 1–10 of 274 research results
-
Jul 8, 2024
Genentech to Re-Introduce Susvimo for Wet AMD
FDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.
-
Jun 13, 2024
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
The company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
Jun 5, 2024
Antabuse Moves into Clinical Trial for People with RP
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
May 22, 2024
ARVO 2024 Highlight: InGel’s Cell Therapy Shows Promise for Preserving Vision
The emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
-
May 16, 2024
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
May 14, 2024
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
The discovery will help geneticists diagnose more RP patients with African descent.
-
May 10, 2024
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Mutations in PDE6B are a leading cause of retinitis pigmentosa.
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Apr 19, 2024
SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease
The company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.
-
Apr 12, 2024
Phase 3 Clinical Trial of NAC Launched for RP Patients
The drug is thought to work independent of the mutated gene causing RP.